SG11202009170UA - Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy - Google Patents
Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapyInfo
- Publication number
- SG11202009170UA SG11202009170UA SG11202009170UA SG11202009170UA SG11202009170UA SG 11202009170U A SG11202009170U A SG 11202009170UA SG 11202009170U A SG11202009170U A SG 11202009170UA SG 11202009170U A SG11202009170U A SG 11202009170UA SG 11202009170U A SG11202009170U A SG 11202009170UA
- Authority
- SG
- Singapore
- Prior art keywords
- immunotherapy
- processes
- production
- same
- tumor infiltrating
- Prior art date
Links
- 238000009169 immunotherapy Methods 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/02—Preservation of living parts
- A01N1/0205—Chemical aspects
- A01N1/021—Preservation or perfusion media, liquids, solids or gases used in the preservation of cells, tissue, organs or bodily fluids
- A01N1/0221—Freeze-process protecting agents, i.e. substances protecting cells from effects of the physical process, e.g. cryoprotectants, osmolarity regulators like oncotic agents
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/02—Preservation of living parts
- A01N1/0236—Mechanical aspects
- A01N1/0242—Apparatuses, i.e. devices used in the process of preservation of living parts, such as pumps, refrigeration devices or any other devices featuring moving parts and/or temperature controlling components
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/46449—Melanoma antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/57—Skin; melanoma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/59—Reproductive system, e.g. uterus, ovaries, cervix or testes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2302—Interleukin-2 (IL-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/998—Proteins not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- Dentistry (AREA)
- Environmental Sciences (AREA)
- Physics & Mathematics (AREA)
- Thermal Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mechanical Engineering (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15/940,901 US10918666B2 (en) | 2017-03-29 | 2018-03-29 | Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy |
PCT/US2018/040474 WO2019190579A1 (en) | 2018-03-29 | 2018-06-29 | Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202009170UA true SG11202009170UA (en) | 2020-10-29 |
Family
ID=63013105
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202009170UA SG11202009170UA (en) | 2018-03-29 | 2018-06-29 | Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy |
Country Status (11)
Country | Link |
---|---|
EP (1) | EP3775165B1 (en) |
KR (1) | KR20200138329A (en) |
CN (1) | CN112513254A (en) |
AU (1) | AU2018415814A1 (en) |
BR (1) | BR112020019496A2 (en) |
CA (1) | CA3094957A1 (en) |
EA (1) | EA202092319A1 (en) |
IL (1) | IL277592A (en) |
MX (1) | MX2020010264A (en) |
SG (1) | SG11202009170UA (en) |
WO (1) | WO2019190579A1 (en) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201522097D0 (en) | 2015-12-15 | 2016-01-27 | Cellular Therapeutics Ltd | Cells |
GB201700621D0 (en) | 2017-01-13 | 2017-03-01 | Guest Ryan Dominic | Method,device and kit for the aseptic isolation,enrichment and stabilsation of cells from mammalian solid tissue |
BR112020018658A2 (en) | 2018-03-15 | 2020-12-29 | KSQ Therapeutics, Inc. | GENE REGULATION COMPOSITIONS AND METHODS FOR IMPROVED IMU-NOTERAPY |
CA3164986A1 (en) | 2019-12-20 | 2021-06-24 | Instil Bio (Uk) Limited | Devices and methods for isolating tumor infiltrating lymphocytes and uses thereof |
US20230106973A1 (en) * | 2020-02-17 | 2023-04-06 | Board Of Regents, The University Of Texas System | Methods for expansion of tumor infiltrating lymphocytes and use thereof |
JP2024501127A (en) | 2020-11-25 | 2024-01-11 | 上海君賽生物科技有限公司 | Tumor-infiltrating lymphocyte culture medium and its use |
AU2021400069A1 (en) * | 2020-12-18 | 2023-07-06 | Instil Bio (Uk) Limited | Processing of tumor infiltrating lymphocytes |
AU2021404204A1 (en) * | 2020-12-18 | 2023-07-06 | Instil Bio (Uk) Limited | Processing of tumor infiltrating lymphocytes |
CN114686430A (en) * | 2020-12-31 | 2022-07-01 | 上海赛比曼生物科技有限公司 | Method for preparing TIL |
WO2022211491A1 (en) * | 2021-03-30 | 2022-10-06 | 주식회사 네오젠티씨 | Method for producing immune cell composition |
EP4355859A1 (en) * | 2021-06-17 | 2024-04-24 | Cbio A/S | Multistep process for culturing tumor-infiltrating lymphocytes for therapeutic use |
WO2023218399A1 (en) * | 2022-05-11 | 2023-11-16 | Fundação D. Anna De Sommer Champalimaud E Dr. Carlos Montez Champalimaud - Centro De Investigação Da Fundação Champalimaud | Method of preparing and expanding a population of immune cells for cancer therapy, potency assay for tumor recognition, biological vaccine preparation and epitope target for antibodies |
Family Cites Families (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4766106A (en) | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
US5206344A (en) | 1985-06-26 | 1993-04-27 | Cetus Oncology Corporation | Interleukin-2 muteins and polymer conjugation thereof |
US6303121B1 (en) | 1992-07-30 | 2001-10-16 | Advanced Research And Technology | Method of using human receptor protein 4-1BB |
US6362325B1 (en) | 1988-11-07 | 2002-03-26 | Advanced Research And Technology Institute, Inc. | Murine 4-1BB gene |
US4902502A (en) | 1989-01-23 | 1990-02-20 | Cetus Corporation | Preparation of a polymer/interleukin-2 conjugate |
US5089261A (en) | 1989-01-23 | 1992-02-18 | Cetus Corporation | Preparation of a polymer/interleukin-2 conjugate |
WO1996032495A1 (en) | 1995-04-08 | 1996-10-17 | Lg Chemicals Ltd. | Monoclonal antibody specific for human 4-1bb and cell line producing same |
CA2268340A1 (en) | 1996-10-11 | 1998-04-23 | Bristol-Myers Squibb Company | Methods and compositions for immunomodulation |
ATE537845T1 (en) | 2000-10-31 | 2012-01-15 | Pr Pharmaceuticals Inc | METHOD FOR PRODUCING FORMULATIONS FOR IMPROVED DELIVERY OF BIOACTIVE MOLECULES |
JP2006500921A (en) | 2002-07-30 | 2006-01-12 | ブリストル−マイヤーズ スクイブ カンパニー | Humanized antibody against human 4-1BB |
CN103173354B (en) | 2003-10-08 | 2017-07-14 | 威尔森沃尔夫制造公司 | The method and device of cell culture is carried out using poromeric material |
US7288638B2 (en) | 2003-10-10 | 2007-10-30 | Bristol-Myers Squibb Company | Fully human antibodies against human 4-1BB |
EP2418278A3 (en) | 2005-05-09 | 2012-07-04 | Ono Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics |
AU2006265108C1 (en) | 2005-07-01 | 2013-01-17 | E. R. Squibb & Sons, L.L.C. | Human monoclonal antibodies to programmed death ligand 1 (PD-L1) |
EP1894940A1 (en) | 2006-08-28 | 2008-03-05 | Apogenix GmbH | TNF superfamily fusion proteins |
CA2860950C (en) | 2007-07-10 | 2017-08-01 | Apogenix Gmbh | Tnf superfamily collectin fusion proteins |
EP2540740B1 (en) | 2008-06-17 | 2014-09-10 | Apogenix GmbH | Multimeric TNF receptors |
EP3103875A1 (en) | 2008-07-21 | 2016-12-14 | Apogenix AG | Tnfsf single chain molecules |
US8475790B2 (en) | 2008-10-06 | 2013-07-02 | Bristol-Myers Squibb Company | Combination of CD137 antibody and CTLA-4 antibody for the treatment of proliferative diseases |
ES2593049T3 (en) | 2009-01-09 | 2016-12-05 | Apogenix Ag | Fusion proteins that form trimers |
US8383099B2 (en) | 2009-08-28 | 2013-02-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Adoptive cell therapy with young T cells |
US8956860B2 (en) | 2009-12-08 | 2015-02-17 | Juan F. Vera | Methods of cell culture for adoptive cell therapy |
US20130115617A1 (en) | 2009-12-08 | 2013-05-09 | John R. Wilson | Methods of cell culture for adoptive cell therapy |
JP2013512694A (en) | 2009-12-08 | 2013-04-18 | ウィルソン ウォルフ マニュファクチャリング コーポレイション | Methods of culturing cells for adoptive cell therapy |
SG10201506906VA (en) | 2010-09-09 | 2015-10-29 | Pfizer | 4-1bb binding molecules |
US8962804B2 (en) | 2010-10-08 | 2015-02-24 | City Of Hope | Meditopes and meditope-binding antibodies and uses thereof |
PL2637694T3 (en) | 2010-11-12 | 2021-10-18 | Nektar Therapeutics | Conjugates of an il-2 moiety and a polymer |
WO2012129201A1 (en) | 2011-03-22 | 2012-09-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of growing tumor infiltrating lymphocytes in gas-permeable containers |
US20140234320A1 (en) | 2011-06-20 | 2014-08-21 | La Jolla Institute For Allergy And Immunology | Modulators of 4-1bb and immune responses |
CN102816734A (en) * | 2012-05-09 | 2012-12-12 | 阮润生 | Method for obtaining tumor antigen-specific T cells |
WO2013173835A1 (en) | 2012-05-18 | 2013-11-21 | Wilson Wolf Manufacturing Corporation | Improved methods of cell culture for adoptive cell therapy |
WO2013188427A1 (en) | 2012-06-11 | 2013-12-19 | Wilson Wolf Manufacturing Corporation | Improved methods of cell culture for adoptive cell therapy |
WO2014133567A1 (en) | 2013-03-01 | 2014-09-04 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of producing enriched populations of tumor-reactive t cells from tumor |
CN105392876B (en) | 2013-06-24 | 2019-07-23 | 威尔逊沃夫制造公司 | Closed system apparatus and method for gas permeability cell cultivation process |
TW201613635A (en) | 2014-02-04 | 2016-04-16 | Pfizer | Combination of a PD-1 antagonist and a 4-1BB agonist for treating cancer |
US20170044496A1 (en) * | 2014-04-10 | 2017-02-16 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Enhanced Expansion of Tumor-Infiltrating Lymphocytes for Adoptive Cell Therapy |
BR112016028996A2 (en) | 2014-06-11 | 2018-01-30 | Polybiocept Ab | lymphocyte expansion composition; method of preparing a population of clinically relevant lymphocytes; immunotherapy for treating or preventing an infectious disease, a cancerous disease, or an autoimmune disease in a mammal; composition for use; kit for use in immunotherapy, in particular for the treatment of a cancerous disease; clinically relevant lymphocyte obtained by a method; and clinically relevant lymphocyte population obtained by a method |
FR3040396A1 (en) * | 2015-06-30 | 2017-03-03 | Chu Nantes | PROCESS FOR CRYOPRESERVATION OF LYMPHOCYTES INFERATING THE TUMOR |
JOP20190224A1 (en) * | 2017-03-29 | 2019-09-26 | Iovance Biotherapeutics Inc | Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy |
-
2018
- 2018-06-29 MX MX2020010264A patent/MX2020010264A/en unknown
- 2018-06-29 CA CA3094957A patent/CA3094957A1/en active Pending
- 2018-06-29 BR BR112020019496-4A patent/BR112020019496A2/en unknown
- 2018-06-29 CN CN201880094012.1A patent/CN112513254A/en active Pending
- 2018-06-29 AU AU2018415814A patent/AU2018415814A1/en active Pending
- 2018-06-29 SG SG11202009170UA patent/SG11202009170UA/en unknown
- 2018-06-29 EA EA202092319A patent/EA202092319A1/en unknown
- 2018-06-29 KR KR1020207031071A patent/KR20200138329A/en not_active Application Discontinuation
- 2018-06-29 EP EP18745741.1A patent/EP3775165B1/en active Active
- 2018-06-29 WO PCT/US2018/040474 patent/WO2019190579A1/en active Application Filing
-
2020
- 2020-09-24 IL IL277592A patent/IL277592A/en unknown
Also Published As
Publication number | Publication date |
---|---|
CN112513254A (en) | 2021-03-16 |
EP3775165A1 (en) | 2021-02-17 |
EA202092319A1 (en) | 2021-03-04 |
KR20200138329A (en) | 2020-12-09 |
CA3094957A1 (en) | 2019-10-03 |
EP3775165B1 (en) | 2024-03-27 |
BR112020019496A2 (en) | 2021-01-12 |
MX2020010264A (en) | 2020-11-06 |
WO2019190579A1 (en) | 2019-10-03 |
AU2018415814A1 (en) | 2020-10-22 |
IL277592A (en) | 2020-11-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL269543A (en) | Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy | |
IL282919A (en) | Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy | |
IL277592A (en) | Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy | |
IL278231A (en) | Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy | |
IL266655A (en) | Remnant tumor infiltrating lymphocytes and methods of preparing and using the same | |
GB2605883B (en) | Tumor infiltrating lymphocytes and methods of therapy | |
IL258599A (en) | Novel peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers | |
SG10202101368WA (en) | Novel peptides and combination of peptides for use in immunotherapy against various cancers | |
HK1252868A1 (en) | Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers | |
SG10202001665QA (en) | Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers | |
EP3370919A4 (en) | Abrasive article and method of making the same | |
GB201511792D0 (en) | Novel peptides and combination of peptides for use in immunotherapy against esopageal cancer and other cancers | |
PL3430027T3 (en) | Peptide for use in immunotherapy against non-small cell lung cancer and small cell lung cancer | |
GB201522667D0 (en) | Novel peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers | |
GB201517538D0 (en) | Novel peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers | |
IL261786A (en) | Peptides and combination of peptides for use in immunotherapy against cancers | |
EP3436217A4 (en) | Elongate shaped abrasive particles, methods of making the same, and abrasive article including the same | |
HK1255541A1 (en) | Novel peptides and combination of peptides for use in immunotherapy against various cancers | |
EP3470385A4 (en) | Silicon carbide production method and silicon carbide composite material |